AD patients experience a long asymptomatic period (preclinical, stage 1) showing only genetic and biomarker abnormalities, with CSF levels of Aβ and tau beginning to rise, accompanied by sleep disorders [44]. This evidence concerns the gene MAPT and Alzheimer disease.